401930-07-2Relevant academic research and scientific papers
Structural basis for constitutive activity and agonist-induced activation of the enteroendocrine fat sensor GPR119
Engelstoft,Norn,Hauge,Holliday,Elster,Lehmann,Jones,Frimurer,Schwartz
supporting information, p. 5774 - 5789 (2015/04/16)
Background and Purpose GPR119 is a Gαs-coupled 7TM receptor activated by endogenous lipids such as oleoylethanolamide (OEA) and by the dietary triglyceride metabolite 2-monoacylglycerol. GPR119 stimulates enteroendocrine hormone and insulin secretion. But despite massive drug discovery efforts in the field, very little is known about the basic molecular pharmacology of GPR119.
ANTAGONISTS OF GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO
-
Page/Page column 58, (2014/05/24)
The present invention relates to compounds of Formula I and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are antagonists of GPR119 useful in the treatment of, for example, a disorder selected from: obesity and diseases/conditions related to obesity such as congestive heart failure, polycystic ovarian syndrome, infertility, gastroesophageal reflux disease, cholelithiasis (gall stones), hernia, erectile dysfunction, urinary incontinence, chronic renal failure, lymphedema, osteoarthritis, hyperuricemia, lower back pain, stroke, headache, asthma, and immobility. In addition, the present antagonists of GPR119 are useful for treating non-alcoholic fatty liver disease, food-dependent Cushing's syndrome, and cancer (e.g., cancers of the esophagus, uterine lining, ovary, kidney, pancreas, and breast; leukemia, multiple myeloma, non-Hodgkin's lymphoma, and colorectal cancer).
